AMGN Amgen

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Biopharmaceutical company focused on innovative therapies for serious illnesses
• • NEW segment emphasis: Integration and conversion of Horizon Therapeutics' equity plans post-acquisition in October 2023

Management Discussion & Analysis

• • Cash and equivalents $9.1B in 2025 vs $12.0B in 2024, decline of $2.9B
• • Long-term debt decreased to $50.0B in 2025 from $56.5B in 2024

Risk Factors

• • Litigation risk: Ongoing U.S. Antitrust trial with Regeneron; jury awarded $135.6M compensatory damages, potential trebling to $406.8M total damages
• • Geopolitical exposure: Patent disputes in Germany and Japan with Sanofi and Regeneron, including upheld EP’004 patent validity and ongoing appeals

Risk Factors

• • New risk: July 31, 2025 MFN Executive Order and July MFN Letter impose potential US drug price mandates affecting Medicaid, Medicare, and commercial payers
• • Updated regulatory risk: IRA Medicare price setting extended to approx. 100 drugs by 2031, with ENBREL and Otezla prices lowered for 2026 and 2027 respectively

Management Discussion & Analysis

• • Revenue $9.56B for Q3 2025, up 12% YoY from $8.15B; driven by volume growth (+14%), offset by net selling price declines (-4%)
• • Operating margin 26.4% (Operating income $2.53B from $2.05B), net income margin 33.6% (Net income $3.22B from $2.83B) for Q3 2025

What are the latest AMGN SEC filings in 2026?

Amgen (AMGN) has filed a 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on April 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did AMGN file its most recent 10-K annual report?

Amgen (AMGN) filed its most recent 10-K annual report on February 13, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view AMGN 10-Q quarterly reports?

Amgen (AMGN)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every AMGN 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has AMGN filed recently?

Amgen (AMGN)'s most recent 8-K was filed on April 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find AMGN insider trading activity (Form 4)?

SignalX aggregates every AMGN Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does AMGN file with the SEC?

Amgen (AMGN) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new AMGN filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Amgen (AMGN).

What is AMGN's SEC CIK number?

Amgen (AMGN)'s SEC CIK (Central Index Key) number is 318154. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 318154 to look up all AMGN filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find AMGN return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Amgen (AMGN) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.